Aopia secures seed round investment

Aopia Biosciences secured seed round of investment to support the development and commercialization of NanoEX™, a next-generation extracellular vesicle (EV) isolation and enrichment platform.

NanoEX™ is based on the patented asymmetric nanopore membrane (ANM) technology and can deliver unparalleled EV isolation efficiency and purity. This highly scalable platform not only allows fast purification of exosomes for research and diagnostic applications, but will also enable large-scale production of therapeutic grade exosomes.